DIFFERENTIAL ROLE OF PROTEIN-KINASE-C IN CYTOKINE-INDUCED LYMPHOCYTE-ENDOTHELIUM INTERACTION IN-VITRO

被引:13
作者
EISSNER, G [1 ]
KOLCH, W [1 ]
MISCHAK, H [1 ]
BORNKAMM, GW [1 ]
HOLLER, E [1 ]
机构
[1] GSF MUNICH, HAMATOL KLIN, D-81377 MUNICH, GERMANY
关键词
D O I
10.1111/j.1365-3083.1994.tb03480.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the present study we investigated the influence of the PKC-inhibitor GF109203X on cytokine- and endotoxin-induced expression of intercellular adhesion molecule 1 (ICAM-1) and on the adhesion of lymphocytes to cytokine-activated endothelial cells. We found that tumour necrosis factor alpha (TNF-alpha)- and lipopolysaccharide (LPS)-induced ICAM-1 expression on a human endothelium-derived cell line (EA.hy926) were unaffected by the PKC-inhibitor and thus appeared to be independent of PKC activation. In contrast, GF109203X significantly reduced ICAM-1 expression induced by interferon-gamma (IFN-gamma) and interleukin-1 (IL-1). The functional relevance of these findings was evaluated in an adhesion assay using human umbilical vein endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBMC). In fact, the IFN-gamma- and IL-1-induced adhesion of PBMC to cytokine treated HUVEC could be down-regulated by the PKC-inhibitor, whereas TNF alpha- and LPS-mediated adhesion was not affected. Additionally, the IL-1-driven ICAM-1 expression on HUVEC as well as the IL-1 induced adhesion of PBMC to HUVEC was found to be TNF-dependent, as both effects could be inhibited by an anti-TNF-alpha monoclonal antibody (MoAb) (MAK195). Based on these data on differential regulation of cytokine-induced lymphocyte-endothelium interactions our study supports the use of PKC-inhibitors as additive modulators in cytokine related pathophysiological conditions.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 23 条
[1]   ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULES [J].
BEVILACQUA, MP .
ANNUAL REVIEW OF IMMUNOLOGY, 1993, 11 :767-804
[2]  
BIRCHALL AM, 1994, J PHARMACOL EXP THER, V268, P922
[3]   THERAPEUTIC POTENTIAL OF PROTEIN-KINASE-C INHIBITORS [J].
BRADSHAW, D ;
HILL, CH ;
NIXON, JS ;
WILKINSON, SE .
AGENTS AND ACTIONS, 1993, 38 (1-2) :135-147
[4]  
CAVENDER D, 1987, J IMMUNOL, V139, P1855
[5]  
CAVENDER DE, 1986, J IMMUNOL, V136, P203
[6]  
DUSTIN ML, 1986, J IMMUNOL, V137, P245
[7]   PERMANENT CELL-LINE EXPRESSING HUMAN FACTOR-VIII-RELATED ANTIGEN ESTABLISHED BY HYBRIDIZATION [J].
EDGELL, CJ ;
MCDONALD, CC ;
GRAHAM, JB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (12) :3734-3737
[8]  
EGUCHI K, 1992, CLIN EXP IMMUNOL, V88, P448
[9]  
HASKARD D, 1986, J IMMUNOL, V137, P2901
[10]   ISOQUINOLINESULFONAMIDES, NOVEL AND POTENT INHIBITORS OF CYCLIC-NUCLEOTIDE DEPENDENT PROTEIN-KINASE AND PROTEIN KINASE-C [J].
HIDAKA, H ;
INAGAKI, M ;
KAWAMOTO, S ;
SASAKI, Y .
BIOCHEMISTRY, 1984, 23 (21) :5036-5041